BioNotebook: Seragon, Arcturus, Seattle Genetics, Cytos, CIRM
This article was originally published in Scrip
Executive Summary
Seragon announces Series A funding amount; Arcturus raises $5m Series A; Seattle Genetics enters clinic with new ADC; Cytos earns Phase IIb cash; and CIRM president steps down.
You may also be interested in...
Arcturus's Differentiated RNA Technology Faces First Clinical Test In 2017
Emerging Company Profile: San Diego-based Arcturus Therapeutics has developed technology for the targeted delivery of RNA therapeutics, which Johnson & Johnson's Janssen subsidiary will evaluate for the first time in humans in a clinical trial starting as early as this year for the partners' hepatitis B drug candidate.
Deals Or No Deals, J.P. Morgan Sets The Tone For 2022
No big buyouts were revealed during the annual J.P. Morgan Healthcare Conference for a third year in a row. Big pharma firms are in acquisition mode, but execs stress desire for easy integrations and scientific alliances.
Lilly Braces For Impact Of CMS Draft Coverage Decision On Biogen’s Aduhelm
The draft national coverage determination, released shortly before Lilly CEO David Ricks spoke at the J.P. Morgan Healthcare Conference, said Medicare will cover anti-amyloid antibodies only for patients in clinical trials, severely limiting commercial potential for Biogen’s Aduhelm and near-term competitors.